LHCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality

BMC Public Health

Volumn 9, Issue , 2009, Pages

  Mühlberger, Nikolai ^a   Schwarzer, Ruth ^a   Lettmeier, Beate ^a   Sroczynski, Gaby ^a   Zeuzem, Stefan ^b   Siebert, Uwe ^a,c,d  

^a UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^b GOETHE UNIVERSITY   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

DISEASE COURSE; EUROPE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; INCIDENCE; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVER TUMOR; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SURVIVAL; VIROLOGY;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EUROPE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MORBIDITY; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 62549157097     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-9-34     Document Type: Article

References (90)

1. Hepatitis C virus infection. GM Lauer BD Walker, New England Journal of Medicine 2001 345 1 41 52 10.1056/NEJM200107053450107 11439948
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. World Health Organization, J Viral Hepat 1999 6 1 35 47 10.1046/j.1365-2893.1999.6120139.x 10847128
3. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. European Association on the Studies on the Liver (EASL), J Hepatol 1999 31 Suppl 1 3 8 10622553
4. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. HJ Alter LB Seeff, Seminars in Liver Disease 2000 20 1 17 35 10.1055/s-2000-9505 10895429
5. Hepatitis C. World Health Organization, Geneva, Switzerland 2002 1 69
6. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection[summary for patients in Ann Intern Med. 2002 Dec 17;137(12):I36; PMID: 12484740]. A Alberti F Noventa L Benvegnu S Boccato A Gatta, Annals of Internal Medicine 2002 137 12 961 964 12484711
7. HCV Infection in Europe. Eurasian Harm Reduction Network (EHRN), 2007 http://www.harm-reduction.org/images/stories/documents/hcv/hcv-in-selected- countries-of-europe-report-final-september.pdf
8. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? JM Miro M Laguno A Moreno A Rimola, J Hepatol 2006 44 1 Suppl S140 145 10.1016/j.jhep.2005.11.028 16352366
9. Pegylated Interferon combined with Ribavirin for chronic hepatitis C virus infection: an economic evaluation [Technology report no 82]. B Brady U Siebert G Sroczynski G Murphy DR Husereau M Sherman W Wong S Mensinkai, Ottawa, Canada: Canadian Agency for Drugs andTechnologies in Health (CADTH) 2007 1 55
10. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. MW Fried ML Shiffman KR Reddy C Smith G Marinos Jr FL Goncales D Haussinger M Diago G Carosi D Dhumeaux, N Engl J Med 2002 347 13 975 982 10.1056/NEJMoa020047 12324553
11. Current therapy for hepatitis C. M Friedrich-Rust S Zeuzem C Sarrazin, Int J Colorectal Dis 2007 22 4 341 349 10.1007/s00384-005-0038-9 16175369
12. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin G Ramadori H Bodenheimer D Bernstein Jr M Rizzetto, Ann Intern Med 2004 140 5 346 355 14996676
13. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht, Lancet 2001 358 9286 958 965 10.1016/S0140-6736(01) 06102-5 11583749
14. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. JB Wong, Pharmacoeconomics 2006 24 7 661 672 10.2165/00019053-200624070-00005 16802842
15. Hepatitis C assays: Operational characteristics (Phase I). World Health Organization, Blood safety and clinical technology Geneva, Switzerland 2001 1 34
16. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. M Buti R San Miguel M Brosa JM Cabases M Medina M Angel Casado L Fosbrook R Esteban, J Hepatol 2005 42 5 639 645 10.1016/j.jhep.2004.12.031 15826711
17. Projecting future complications of chronic hepatitis C in the United States. GL Davis JE Albright SF Cook DM Rosenberg, Liver Transpl 2003 9 4 331 338 10.1053/jlts.2003.50073 12682882
18. Modeling the hepatitis C virus epidemic in France. S Deuffic L Buffat T Poynard AJ Valleron, Hepatology 1999 29 5 1596 1601 10.1002/hep.510290528 10216148
19. Simulation of hepatitis C based on a mandatory reporting system. M Sagmeister EL Renner B Mullhaupt JB Wong, Eur J Gastroenterol Hepatol 2002 14 1 25 34 10.1097/00042737-200201000-00006 11782572
20. Estimating future hepatitis C morbidity, mortality, and costs in the United States. JB Wong GM McQuillan JG McHutchison T Poynard, Am J Public Health 2000 90 10 1562 1569 11029989 10.2105/AJPH.90.10.1562
21. Prediction of hepatitis C burden in Canada. S Zou M Tepper S El Saadany, Can J Gastroenterol 2000 14 7 575 580 10978943
22. The changing epidemiology of hepatitis C virus infection in Europe. JI Esteban S Sauleda J Quer, J Hepatol 2008 48 1 148 162 10.1016/j.jhep.2007.07.033 18022726
23. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Hepatitis C and injecting drug use: impact, costs and policy options. Monograph 7 Lisbon: European Monitoring Centre for Drugs and Drug Addiction 2004
24. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Annual report 2008: the state of the drugs problem in Europe Luxembourg: Office for Official Publications of the European Communities 2008
25. Hepatitis C. World Health Organization, 1999 http://www.who.int/ immunization/topics/hepatitis-c/en/index.html/
26. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. National Institute of Health (NIH), Hepatology 2002 36 5 Suppl 1 S3 20 12407572
27. Global burden of disease (GBD) for hepatitis C. The Global Burden of Disease Working Group, J Clin Pharmacol 2004 44 1 20 29 10.1177/0091270003258669 14681338
28. WHO Regional Office for Europe: Country information. World Health Organization, 2006 http://www.euro.who.int/countryinformation
29. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. JF Perz GL Armstrong LA Farrington YJ Hutin BP Bell, J Hepatol 2006 45 4 529 538 10.1016/j.jhep.2006.05. 013 16879891
30. The global health burden of infection-associated cancers in the year 2002. DM Parkin, Int J Cancer 2006 118 12 3030 3044 10.1002/ijc.21731 16404738
31. Global Burden of Disease and Risk Factors New York: Oxford University Press 2006
32. Quantifying the burden of disease: the technical basis for disability-adjusted life years. CJ Murray, Bull World Health Organ 1994 72 3 429 445 8062401
33. Quantifying disability: data, methods and results. CJ Murray AD Lopez, Bull World Health Organ 1994 72 3 481 494 8062403
34. The utility of DALYs for public health policy and research: a reply. CJ Murray AD Lopez, Bull World Health Organ 1997 75 4 377 381 9342897
35. Global Burden of Disease in 2002: data sources, methods and results. CD Mathers C Bernard KM Iburg M Inoue D Ma Fat K Shibuya C Stein N Tomijima, GPE Discussion Paper No 54 Geneva, Switzerland: World Health Organization 2003 1 118 http://www.who.int/healthinfo/paper54.pdf
36. Calculating QALYs, comparing QALY and DALY calculations. F Sassi, Health Policy Plan 2006 21 5 402 408 10.1093/heapol/czl018 16877455
37. WHO Health for all database. World Health Organization, 2006 http://data.euro.who.int/hfadb
38. Hepatitis C: global prevalence. World Health Organization, Wkly Epidemiol Rec 1997 72 46 341 344 9385865
39. Hepatitis C-global prevalence (update). World Health Organization, Wkly Epidemiol Rec 1999 74 49 425 427 10645164
40. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. S Touzet L Kraemer C Colin P Pradat D Lanoir F Bailly RC Coppola S Sauleda MR Thursz H Tillmann, European Journal of Gastroenterology & Hepatology 2000 12 6 667 678 10.1097/00042737-200012060- 00017 10912488
41. Prevalence, incidence and duration. J Freeman GB Hutchison, Am J Epidemiol 1980 112 5 707 723 6969024
42. B MacMahon D Trichopoulos, Epidemiology - Principles and Methods Boston, New York, Toronto, London: Little, Brown and Company 2 1996
43. The Global Burden of Disease project: results for 2002 and earlier years, methods, documentation and publications. Manuals, resources and software for carrying out national burden of disease studies. World Health Organization, http://www.who.int/healthinfo/bodproject/en/index.html
44. Mortality and burden of disease estimates for WHO member states in 2002. World Health Organization, 2004 http://www.who.int/whosis/en/
45. Estimates of Years Lost due to Disability by sex, cause and WHO Region for 2002. World Health Organization, 2004 http://www.who.int/entity/healthinfo/ statistics/gbdwhoregionyld2002.xls
46. International Figures on organ donation and transplantation - 2004. Transplant Committee of the Council of Europe (TCCE), Newsletter Transplant 2005 10 1 1 44
47. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. R Adam P McMaster JG O'Grady D Castaing JL Klempnauer N Jamieson P Neuhaus J Lerut M Salizzoni S Pollard, Liver Transpl 2003 9 12 1231 1243 10.1016/j.lts.2003.09.018 14625822
48. ECDC, Annual epidemiological report on communicable diseases in Europe 2007
49. Surveillance and epidemiology of hepatitis B and C in Europe - a review. M Rantala MJ van de Laar, Euro Surveill 2008 13 21 18761967
50. European Health Report. World Health Organization, WHO Regional Publications, European Series Copenhagen, Denmark: WHO Regional Office for Europe 2002 1 165
51. The challenge of hepatitis C surveillance in Europe. JC Desenclos, Euro Surveill 2003 8 5 99 100 12799475
52. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2005. http://rki.de
53. Role of a sentinel surveillance system in the context of global surveillance of infectious diseases. I Arita M Nakane K Kojima N Yoshihara T Nakano A El-Gohary, Lancet Infect Dis 2004 4 3 171 177 10.1016/S1473-3099(04) 00942-9 14998504
54. Emerging infectious diseases in Russia. SV Netesov JL Conrad, Emerging Infectious Diseases 2001 7 1 1 5 11266288
55. Global epidemiology and burden of hepatitis C. WR Kim, Microbes and Infection 2002 4 1219 1225 10.1016/S1286-4579(02)01649-0
56. Guidelines for Second Generation HIV Surveillance for HIV: The Next Decade (2000). UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, 2000 http://www.who.int/hiv/pub/surveillance/en/cds-edc-2000-5.pdf
57. Evaluation of hepatitis C surveillance in Poland in 1998. J Mazurek Y Hutin LA McNutt DL Morse, Epidemiol Infect 2002 129 1 119 125 10.1017/S0950268802007124 12211578
58. EUROSTAT Jahrbuch. Der statistische Wegweiser durch Europa. EUROSTAT, Luxembourg: Europäische Kommission. Amt für amtliche Veröffentlichungen der Europäischen Gemeinschaften 2002 1 460
59. Epidemiology of hepatitis C virus (HCV) infection. T Sy MM Jamal, Int J Med Sci 2006 3 2 41 46 16614741
60. Five million Americans infected with hepatitis C virus: a corrected estimate [abstract #44]. BR Edlin, Oral Presentation at the 56th Annual Meeting of the American Association for the Study of Liver Diseases: 2005 Boston, MA, USA. Hepatology 2005 213A
61. Injection drug users: the overlooked core of the hepatitis C epidemic. BR Edlin MR Carden, Clin Infect Dis 2006 42 5 673 676 16447113 10.1086/499960
62. Strengthening Immunisation Systems and Introduction of Hepatitis B Vaccine in Central and Eastern Europe and the Newly Independent States. Report of a meeting organised by the Centers for Disease Control and Prevention, Children's Vaccine Programme at the Programme for Appropriate Technology in Health, the Global Alliance for Vaccines and Immunisation, the United Nations Children's Fund, the Viral Hepatitis Prevention Board, and the World Health Organization. A Levitt A Vorsters N Emiroglu S Goldstein T Godal M Kane D Popovic S Wiersma P Van Damme, Kyiv, Ukraine 2004 1 55
63. The UK vs. Europe: Losing the fight against hepatitis C. The Hepatitis C Trust and the University of Southampton, 2005 http://www.hepcuk.info/data/news/ 213-The%20UK%20vs.%20Europe.pdf
64. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. P Pradat E Caillat-Vallet F Sahajian F Bailly G Excler M Sepetjan C Trepo J Fabry A members, European Journal of Epidemiology 2001 17 1 47 51 10.1023/A:1010902614443 11523575
65. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. W Thierfelder W Hellenbrand H Meisel E Schreier R Dortschy, European Journal of Epidemiology 2001 17 5 429 435 10.1023/A:1013792013184 11855576
66. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. F Ansaldi B Bruzzone S Salmaso MC Rota P Durando R Gasparini G Icardi, Journal of Medical Virology 2005 76 3 327 332 10.1002/jmv.20376 15902713
67. Prevalence of hepatitis C virus infection in the general population of northern Spain[see comment]. S Riestra E Fernandez P Leiva S Garcia G Ocio L Rodrigo, European Journal of Gastroenterology & Hepatology 2001 13 5 477 481 10.1097/00042737-200105000-00003 11396524
68. The prevalence of hepatitis C in England and Wales. MA Balogun ME Ramsay LM Hesketh N Andrews KP Osborne NJ Gay P Morgan-Capner, J Infect 2002 45 4 219 226 10.1053/jinf.2002.1059 12423608
69. Estimates of numbers of deaths by sex, cause and WHO Region for 2002. World Health Organization, 2004 http://www.who.int/healthinfo/statistics/ gbdwhoregionmortality2002.xls
70. Mortality by cause for eight regions of the world: Global Burden of Disease Study. CJ Murray AD Lopez, Lancet 1997 349 9061 1269 1276 10.1016/S0140-6736(96)07493-4 9142060
71. Primary liver cancer: worldwide incidence and trends. FX Bosch J Ribes M Diaz R Cleries, Gastroenterology 2004 127 5 Suppl 1 S5 S16 10.1053/j.gastro. 2004.09.011 15508102
72. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. G Montalto M Cervello L Giannitrapani F Dantona A Terranova LA Castagnetta, Ann N Y Acad Sci 2002 963 13 20 12095924
73. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. E Sagnelli T Stroffolini A Mele P Almasio N Coppola L Ferrigno C Scolastico M Onofrio M Imparato P Filippini, Journal of Medical Virology 2005 75 4 522 527 10.1002/jmv.20313 15714480
74. Etiological factor of hepatocellular carcinoma in Italy. T Stroffolini T Stroffolini, Minerva Gastroenterologica e Dietologica 2005 51 1 1 5 15756142
75. Alcohol use and hepatitis C. MG Peters NA Terrault, Hepatology 2002 36 5 Suppl 1 S220 225 10.1002/hep.1840360728 12407597
76. Global epidemiology of hepatitis C virus infection. CW Shepard L Finelli MJ Alter, Lancet Infect Dis 2005 5 9 558 567 10.1016/S1473-3099(05)70216-4 16122679
77. Estimates of DALYs by sex, cause and WHO Region for 2002. World Health Organization, 2004 http://www.who.int/healthinfo/statistics/ gbdwhoregiondaly2002.xls
78. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. BM Spiegel ZM Younossi RD Hays D Revicki S Robbins F Kanwal, Hepatology 2005 41 4 790 800 10.1002/hep.20659 15791608
79. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. GR Foster RD Goldin HC Thomas, Hepatology 1998 27 1 209 212 10.1002/hep.510270132 9425939
80. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. CA Lang S Conrad L Garrett D Battistutta WG Cooksley MP Dunne GA Macdonald, J Pain Symptom Manage 2006 31 4 335 344 10.1016/j.jpainsymman.2005.08.016 16632081
81. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. A Hollander GR Foster O Weiland, Scand J Gastroenterol 2006 41 5 577 585 10.1080/00365520500325952 16638701
82. Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. M von Wagner JH Lee B Kronenberger R Friedl C Sarrazin G Teuber E Herrmann S Zeuzem, J Viral Hepat 2006 13 12 828 834 10.1111/j.1365-2893.2006.00772.x 17109682
83. U Siebert G Sroczynski on behalf of the German Hepatitis C Model (GEHMO) Group and the HTA Expert Panel on Hepatitis C, [Antiviral therapy for patients with chronic hepatitis C in Germany. Evaluation of effectiveness and cost-effectiveness of initial combination therapy with Interferon/Peginterferon plus Ribavirin. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security] Köln: DIMDI 2003 8
84. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. U Siebert G Sroczynski on behalf of the German Hepatitis C Model (GEHMO) Group and the HTA Expert Panel on Hepatitis C, Int J Technol Assess Health Care 2005 21 1 55 65 10.1017/S0266462305050075 15736515
85. Health-state utilities and quality of life in hepatitis C patients. CA Chong A Gulamhussein EJ Heathcote L Lilly M Sherman G Naglie M Krahn, Am J Gastroenterol 2003 98 3 630 638 10.1111/j.1572-0241.2003.07332.x 12650799
86. Performance of different utility assessment methods in chronic hepatitis C patients. U Siebert U Ravens-Sieberer W Greiner G Sroczynski JB Wong KM Kuntz B Kallinowski JM Graf von der Schulenburg M Bullinger S Rossol, Proceedings of the 19th Plenary Meeting of the EuroQol Group 13th-14th September 2002 Discussion Papers York, UK: Centre for Health Economics, University of York, Kind P, Macran S, 2003 175 184
87. Uncertainty and data availability for the global burden of disease estimates 2000-2002. CD Mathers, 2005 http://www.who.int/healthinfo/ publications/boduncertaintypaper2002.pdf
88. Hepatitis C. World Health Organization, 2006 http://www.who.int/ immunization/topics/hepatitis-c/en/index.html
89. [Liver transplantation in Germany]. M Wolff JC Kalff NT Schwarz H Lauschke T Minor RH Tolba A Hirner, Zentralbl Chir 2003 128 10 831 841 10.1055/s-2003-44344 14628232
90. The natural history of hepatitis C virus (HCV) infection. SL Chen TR Morgan, Int J Med Sci 2006 3 2 47 52 16614742